Labrys Biologics
Welcome to  Labrys Biologics

Upcoming Conferences

March 28, 2014

Future Leaders in the Biotech Industry

New York City  (more)

April 26 - May 3, 2014

American Academy of Neurology 2014 Annual Meeting

Philadelphia, Pennsylvania, USA  (more)

April 29 - 30, 2014

Allicense Conference 2014

San Francisco, CA, USA  (more)

Labrys Biologics is a private, venture-financed development stage biotechnology company focused on treatments for chronic migraine and high frequency episodic migraine. Labrys’ lead candidate, LBR-101 (formerly known as RN-307), is an anti-CGRP monoclonal antibody which has completed Phase 1. Founded in late 2012, Labrys is backed by venBio, Canaan Partners, InterWest Partners and Sofinnova Ventures.

Latest News

January 8, 2014

Labrys Biologics Initiates Two Phase 2 Studies of LBR-101 for the Prevention of Chronic and Episodic Migraine

June 26, 2013

Labrys Biologics Presents LBR-101 Late-breaking Data at 2013 International Headache Conference

More News